Abstract
TP53 is mutated in 10 to 15% of cases of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) and is associated with a previous exposure to cytotoxic therapy, complex cytogenetic abnormalities, and a poor prognosis. Recent data have established the importance of TP53-mutant allele status, the determination of which requires specific genetic testing. Compared with monoallelic disease, multihit TP53-mutant AML/MDS is associated with chromosomal abnormalities and decreased overall survival. Most TP53 mutations are missense mutations that localize to the DNA binding domain. Hot-spot mutations involving residues R175, Y220, G245, R248, R273, or R282 represent approximately 35% of all TP53 missense mutations in AML/MDS. There is evidence that these hot-spot mutations may have dominant negative or gain-of-function properties. Here we review this evidence and discuss its potential impact on patient outcomes and clinical management.
References
1.
Bernard
E
, Nannya
Y
, Hasserjian
RP
, et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
. Nat Med
. 2020
;26
(10
):1549
-1556
.2.
Grob
T
, Al Hinai
ASA
, Sanders
MA
, et al. Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome
. Blood
. 2022
;139
(15
):2347
-2354
.3.
Jambhekar
A
, Ackerman
EE
, Alpay
BA
, Lahav
G
, Lovitch
SB
. Comparison of TP53 mutations in myelodysplasia and acute leukemia suggests divergent roles in initiation and progression
. Blood Neoplasia
. 2024
;1
(1
):100004
.4.
Tashakori
M
, Kadia
T
, Loghavi
S
, et al. TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia
. Blood
. 2022
;140
(1
):58
-72
.5.
Abel
HJ
, Oetjen
KA
, Miller
CA
, et al. Genomic landscape of TP53-mutated myeloid malignancies
. Blood Adv
. 2023
;7
(16
):4586
-4598
.6.
Wong
TN
, Ramsingh
G
, Young
AL
, et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia
. Nature
. 2015
;518
(7540
):552
-555
.7.
Arber
DA
, Orazi
A
, Hasserjian
RP
, et al. International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data
. Blood
. 2022
;140
(11
):1200
-1228
.8.
Hasserjian
RP
, Orazi
A
, Orfao
A
, Rozman
M
, Wang
SA
. The International Consensus Classification of myelodysplastic syndromes and related entities
. Virchows Arch
. 2023
;482
(1
):39
-51
.9.
Khoury
JD
, Solary
E
, Abla
O
, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms
. Leukemia
. 2022
;36
(7
):1703
-1719
.10.
Duncavage
EJ
, Schroeder
MC
, O'Laughlin
M
, et al. Genome sequencing as an alternative to cytogenetic analysis in myeloid cancers
. N Engl J Med
. 2021
;384
(10
):924
-935
.11.
Short
NJ
, Montalban-Bravo
G
, Hwang
H
, et al. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia
. Blood Adv
. 2020
;4
(22
):5681
-5689
.12.
Swoboda
DM
, Kanagal-Shamanna
R
, Brunner
AM
, et al. Marrow ring sideroblasts are highly predictive for TP53 mutation in MDS with excess blasts
. Leukemia
. 2022
;36
(4
):1189
-1192
.13.
Giacomelli
AO
, Yang
X
, Lintner
RE
, et al. Mutational processes shape the landscape of TP53 mutations in human cancer
. Nat Genet
. 2018
;50
(10
): 1381
-1387
.14.
Boettcher
S
, Miller
PG
, Sharma
R
, et al. A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies
. Science
. 2019
;365
(6453
):599
-604
.15.
Aubrey
BJ
, Janic
A
, Chen
Y
, et al. Mutant TRP53 exerts a target gene-selective dominant-negative effect to drive tumor development
. Genes Dev
. 2018
;32
(21-22
):1420
-1429
.16.
Wang
Z
, Burigotto
M
, Ghetti
S
, et al. Loss-of-function but not gain-of- function properties of mutant TP53 are critical for the proliferation, survival, and metastasis of a broad range of cancer cells
. Cancer Discov
. 2024
; 14
(2
):362
-379
.17.
Hanel
W
, Marchenko
N
, Xu
S
, Yu
SX
, Weng
W
, Moll
U.
Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis
. Cell Death Differ
. 2013
;20
(7
):898
-909
.18.
Lang
GA
, Iwakuma
T
, Suh
YA
, et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome
. Cell
. 2004
;119
(6
): 861
-872
.19.
Olive
KP
, Tuveson
DA
, Ruhe
ZC
, et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
. Cell
. 2004
;119
(6
):847
-860
.20.
Liu
DP
, Song
H
, Xu
Y.
A common gain of function of p53 cancer mutants in inducing genetic instability
. Oncogene
. 2010
;29
(7
):949
-956
.21.
Song
H
, Hollstein
M
, Xu
Y.
p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM
. Nat Cell Biol
. 2007
;9
(5
):573
-580
.22.
Xiong
S
, Chachad
D
, Zhang
Y
, et al. Differential gain-of-function activity of three p53 hotspot mutants in vivo
. Cancer Res
. 2022
;82
(10
): 1926
-1936
.23.
Loizou
E
, Banito
A
, Livshits
G
, et al. A gain-of-function p53-mutant oncogene promotes cell fate plasticity and myeloid leukemia through the pluripotency factor FOXH1
. Cancer Discov
. 2019
;9
(7
):962
-979
.24.
Rajagopalan
A
, Feng
Y
, Gayatri
MB
, et al. A gain-of-function p53 mutant synergizes with oncogenic NRAS to promote acute myeloid leukemia in mice
. J Clin Invest
. 2023
;133
(24
).25.
Kotler
E
, Shani
O
, Goldfeld
G
, et al. A systematic p53 mutation library links differential functional impact to cancer mutation pattern and evolutionary conservation
. Mol Cell
. 2018
;71
(5
):873
.26.
Bougeard
G
, Renaux-Petel
M
, Flaman
JM
, et al. Revisiting Li-Fraumeni syndrome from TP53 mutation carriers
. J Clin Oncol
. 2015
;33
(21
):2345
-2352
.27.
Hainaut
P
, Pfeifer
GP
. Somatic TP53 mutations in the era of genome sequencing
. Cold Spring Harb Perspect Med
. 2016
;6
(11
):a026179
.28.
Hassin
O
, Nataraj
NB
, Shreberk-Shaked
M
, et al. Different hotspot p53 mutants exert distinct phenotypes and predict outcome of colorectal cancer patients
. Nat Commun
. 2022
;13
(1
):2800
.29.
Poeta
ML
, Manola
J
, Goldwasser
MA
, et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck
. N Engl J Med
. 2007
;357
(25
):2552
-2561
.30.
Neskey
DM
, Osman
AA
, Ow
TJ
, et al. Evolutionary action score of TP53 identifies high-risk mutations associated with decreased survival and increased distant metastases in head and neck cancer
. Cancer Res
. 2015
; 75
(7
):1527
-1536
.31.
Dutta
S
, Pregartner
G
, Rücker
FG
, et al. Functional classification of TP53 mutations in acute myeloid leukemia
. Cancers (Basel)
. 2020
;12
(3
).32.
Xia
J
, Miller
CA
, Baty
J
, et al. Somatic mutations and clonal hematopoiesis in congenital neutropenia
. Blood
. 2018
;131
(4
):408
-416
.33.
Carter
BZ
, Mak
PY
, Ke
B
, et al. Selective targeting of TP53-Y220C mutant AML by PC14586 results in TP53 wild-type conformation and synergistical apoptosis induction by concomitant inhibition of Xpo-1, MDM2, or Bcl-2
. Blood
. 2023
;142
(suppl 1
):2261
.34.
Guiley
KZ
, Shokat
KM
. A small molecule reacts with the p53 somatic mutant Y220C to rescue wild-type thermal stability
. Cancer Discov
. 2023
;13
(1
): 56
-69
.35.
Hsiue
EH
, Wright
KM
, Douglass
J
, et al. Targeting a neoantigen derived from a common TP53 mutation
. Science
. 2021
;371
(6533
).Copyright © 2024 by The American Society of Hematology
2024
You do not currently have access to this content.
